To include your compound in the COVID-19 Resource Center, submit it here.

Ablynx's caplacizumab meets in Phase III for TTP

Ablynx N.V. (Euronext:ABLX) reported top-line data showing that caplacizumab (ALX-0081/ALX-0681) met the primary endpoint in the double-blind, international Phase III HERCULES trial to treat acquired thrombotic thrombocytopenic purpura (TTP). The company has already submitted an MAA to

Read the full 378 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE